genprowebdirectory
News
Insights
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
BioPerspectives
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
News
News
CRISPR-Cas9 Goes Immuno-Incognito
News
University of California, U. Vienna, Charpentier Awarded Fourth U.S. CRISPR-Cas9 Patent
Artificial Intelligence
PTSD Diagnosed through Voice Analysis Using AI
News
Personalized, Combination Therapies Improve Cancer Patient Outcomes
News
Lilly, Avidity to Partner on Immunology Drugs in Up-to-$440M Collaboration
Insights
Insights
Urine-Based Liquid Biopsy for Nonurological Cancers
Insights
Top 10 Best-Selling Cancer Drugs of 2018
GWAS
Genetic Basis of Obesity Carries Weight
Insights
Liquid Biopsy: An Old Concept with a New Twist
CAR T-Cells
Preparing U.S. Healthcare Insurance for High-Cost Curative Therapies
A-Lists
Insights
Top 10 Best-Selling Cancer Drugs of 2018
Insights
Top 10 Sequencing Companies
Insights
Top 10 Immuno-Oncology Collaborations
A-Lists
Top 15 Best-Selling Drugs of 2018
March 2019 Vol. 39 No. 3
Top 10 Immuno-Oncology Startups
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
News
CRISPR-Cas9 Goes Immuno-Incognito
News
University of California, U. Vienna, Charpentier Awarded Fourth U.S. CRISPR-Cas9 Patent
News
Personalized, Combination Therapies Improve Cancer Patient Outcomes
Insights
Urine-Based Liquid Biopsy for Nonurological Cancers
Magazine
April 2019 Vol. 39 No. 4
Functional Ultrasound
Commentary
Linear DNA Crosses the Line between Tags and Therapeutics
April 2019 Vol. 39 No. 4
Nucleic Acid Extraction: Extremely Fast, Extremely Simple, Extremely Effective
April 2019 Vol. 39 No. 4
CRISPR and Beyond: Advances in Gene Therapy
April 2019 Vol. 39 No. 4
Epigenetic Therapies Return Cells to the Straight and Narrow
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
BioPerspectives
Upcoming Webinars
How to Decrease Long Read Sequencing Sample QC Time by 10-Fold
Videos
The First Computer-Generated Bacterial Genome
April 2019 Vol. 39 No. 4
Functional Ultrasound
Upcoming Webinars
De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Home
Companies
Amgen
Amgen
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Amgen
Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other “Serious” Illnesses
Amgen
Amgen Selects Second Cancer Target in 2-Year-Old Collaboration with Nuevolution
Amgen
Amgen, MD Anderson Launch Two Cancer Collaborations
Amgen
Amgen, Novartis Set to Launch Migraine Drug Aimovig Next Week after FDA Approval
Amgen
Federal Circuit Favors Novartis’ Sandoz over Amgen in Biosimilar “Patent Dance” Dispute
Amgen
Amgen, Novartis Expand Alzheimer’s Collaboration with New Trial
Amgen
Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration
Amgen
Amgen Delaying U.S. Launch of Humira Biosimilar in Settlement with AbbVie
Amgen
After FDA Approval, Amgen–Allergan Cancer Biosimilar Mvasi Faces Launch, Pricing Challenges
Amgen
FDA to Review BLA for Amgen-Novartis Migraine Prevention Treatment
Amgen
Amgen Licenses Ligand’s Captisol Technology for AML Candidate AMG 330
Amgen
FDA Rejects Amgen-UCB Osteoporosis Candidate Evenity
Amgen
EC Clears Sandoz’s Erelzi Biosimilar Etanercept Copy of Amgen’s Enbrel
Amgen
Supreme Court’s Sandoz–Amgen Decision Boosts Biosimilars
Amgen
Amgen Sues to Reverse FDA Denial of Pediatric Exclusivity for Sensipar
Load more
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
